The new asymmetry index from researchers at Universitat Oberta de Catalunya and collaborators quantifies regional gray matter loss in Alzheimer's, revealing patterns missed by symmetric assumptions in traditional imaging. Published in Brain Communications (2025), this observational study analyzed MRI data from 60 patients at Hospital Clínic de Barcelona and 564 from the DIAN cohort, an international genetic Alzheimer's registry led by Washington University. Unlike RCTs, this design relies on cross-sectional and limited longitudinal cohorts without randomization, limiting causal claims but strengthening biomarker correlation with plasma neurofilament light and cognitive scores. Prior work, including 2023 studies in Neurology on hippocampal asymmetry, showed healthy aging produces bilateral thinning while frontotemporal dementia drives marked lateralization; Alzheimer's occupies an intermediate state the index now measures continuously. Original coverage underplayed integration potential with emerging blood-based biomarkers and failed to note the small genetic-case sample (under 1% of all Alzheimer's) may not generalize to sporadic disease. This tool could refine trial endpoints for anti-amyloid therapies by detecting subtle progression earlier than whole-brain volume metrics, though conflicts of interest around DIAN industry partnerships warrant scrutiny in future validation.